Background: GRAP2 is an adaptor protein involved in leukocyte signal activation; however, the prognostic value of GRAP2 and its correlation with immune cell in ltration in lung adenocarcinoma (LUAD) is unclear.Methods: Original data were downloaded from the TCGA database and Gene Expression Omnibus (GEO) database. GRAP2 expression was analyzed with the TCGA and TIMER databases. We evaluated the in uence of GRAP2 on clinical prognosis using the Kaplan-Meier plotter, GEO database and GEPIA database. TIMER and TISIDB databases were used to investigate correlations between GRAP2 expression and cancer immune characteristics. Finally, we con rmed the expression of GRAP2 in LUAD by immunohistochemistry staining.Results: Transcription levels of GRAP2 were signi cantly lower in several human cancers, including LUAD, than in adjacent normal tissues. We also found that tumor tissues have lower protein expression levels of GRAP2 compared with adjacent normal tissues in LUAD by immunohistochemistry staining. The downregulated GRAP2 was associated with poorer overall survival, pathologic stage, T stage, N stage and primary therapy outcome in LUAD. Mechanically, we found a hub gene set that included a total of 91 genes co-expressed with GRAP2, which were closely related to immune response in LUAD. Expression levels of GRAP2 were positively correlated with in ltrating levels of B cells, CD8 + T cells, dendritic cells, eosinophils, macrophages, mast cells, Th2 cells, Th1 cells, Th17 cells, NK cells and neutrophils. GRAP2 expression levels also affected the cumulative survival time of B cells and dendritic cells. GRAP2 expression is positively correlated with multiple immune markers, chemokines, chemokine receptors and MHC molecules of LUAD.Conclusions: These ndings suggest that GRAP2 is a tumor suppressor gene and can be used as a prognostic biomarker for assessing prognosis and immune in ltration level in LUAD.